Letter: TNFα inhibitors and prevalence of fatty liver disease in chronic inflammatory diseases

E-ISSN： 1365-2036|42|4|489-489

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.4, 2015-08, pp. : 489-489

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Detection of Helicobacter species in chronic liver disease and chronic inflammatory bowel disease

By Veijola Lea Nilsson Ingrid Halme Leena Al-Soud Waleed Abu Mäkinen Judit Ljungh Åsa Rautelin Hilpi

Annals of Medicine, Vol. 39, Iss. 7, 2007-01 ,pp. : 554-560

Informa Healthcare

Access to resources Recommend Favorite

Errors in meta‐analysis on prevalence of nonalcoholic fatty liver disease

HEPATOLOGY, Vol. 64, Iss. 4, 2016-10 ,pp. : 1389-1390

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: proton pump inhibitors ‐ severity of liver disease and mortality in patients with cirrhosis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 7, 2015-04 ,pp. : 704-705

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevalence of pruritus in patients with chronic liver disease: A multicenter study

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E252-E262

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: diverticulosis in inflammatory bowel diseases

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 39, Iss. 8, 2014-04 ,pp. : 899-900

John Wiley & Sons Inc

Access to resources Recommend Favorite